S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

CRDF Cardiff Oncology Inc

3.17

-0.14 (-4.23%)

After Hours

Last Updated: 16:44:21

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Cardiff Oncology Charts.

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Cardiff Oncology Charts.

Trovagene, Inc. News

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Thursday 2 May 2024 (6 days ago) • GlobeNewswire Inc.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Thursday 25 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Monday 8 April 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Wednesday 6 March 2024 (2 months ago) • GlobeNewswire Inc.

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)

More Trovagene, Inc. News Articles

Brookmount Explorations (PK)

MicroCloud Hologram

Ronn Motor (PK)

Globestar Therapeutics (PK)

Decentral Life (PK)

Auto Parts 4Less (PK)

Nexus Energy Services (PK)

Bioelectronics (PK)

Elite Pharmaceuticals (QB)

Kona Gold Beverage (PK)

Greene Concepts (PK)

Intergrated Cannabis Sol... (PK)

Valiant Eagle (PK)

FuelCell Energy

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions